Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2021-06-11 Earnings Release
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Autolus to present additional data in AUTO1
Earnings Release Classification · 99% confidence The document is an announcement released via RNS (RNS Number : 6265B) by Syncona Limited regarding an update from its portfolio company, Autolus Therapeutics Plc, concerning new data presentation at the European Hematology Association (EHA) Virtual Congress 2021. The text explicitly states that the full announcement from Autolus is contained below and mentions that management will host a conference call and webcast to discuss the data. This structure—an initial announcement by a listed entity (Syncona) referencing and including the full text of a material update from a portfolio company, often related to clinical trial data or corporate events—is characteristic of a general regulatory news service release. Since the document is primarily disseminating news about clinical data and an upcoming call, and it is explicitly formatted as an RNS release, it fits best under the general regulatory announcement category, as it is not a full Earnings Release (ER), Interim Report (IR), or Investor Presentation (IP) itself, but rather a notification of these events/data releases. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for this type of market-sensitive news dissemination that isn't a core financial report or specific corporate action filing. Q2 2021
2021-06-11 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (2903 characters) released via RNS (London Stock Exchange news service). The title is "Notice of Final Results" and the text explicitly states that the company "will announce its final results for the year ended 31 March 2021 on Thursday 17 June 2021." This structure—a brief notice informing the market about the future publication date of a substantive report (Final Results)—fits the definition of a Report Publication Announcement (RPA). It is not the full report itself, nor is it a general regulatory filing (RNS) since a more specific category (RPA) applies based on the 'MENU VS MEAL' rule.
2021-05-18 English
Freeline reports Q1 results
Earnings Release Classification · 100% confidence The document is an RNS announcement by Syncona Limited, noting that its portfolio company, Freeline Therapeutics, announced its 'financial results for the first quarter 2021' and provided business highlights. The text explicitly states that the announcement can be accessed on Freeline's website and that the 'full text of the announcement from Freeline is contained below.' The content below the initial notice is the full text of Freeline's Q1 2021 financial results press release, including detailed financial tables for the three months ended March 31, 2021. Since the primary document is an announcement *about* the release of financial results, and it contains the full results, it fits the definition of an Interim/Quarterly Report (IR) or an Earnings Release (ER). However, the structure strongly suggests this is the comprehensive report content itself, detailing the financial performance for the quarter (Q1 2021). The presence of detailed comparative financial tables (P&L and Balance Sheet data for Q1 2021 vs Q4 2020/Q1 2020) points towards a comprehensive report rather than just the initial highlights (ER). Therefore, 'Interim / Quarterly Report' (IR) is the most appropriate classification for the embedded content, even though the wrapper is an RNS filing. Q1 2021
2021-05-18 English
Autolus to present additional data in AUTO1
Earnings Release Classification · 99% confidence The document begins with an RNS Number and is dated May 12, 2021. It is an announcement from Syncona Limited regarding its portfolio company, Autolus Therapeutics, presenting new data at the European Hematology Association (EHA) Virtual Congress. The text explicitly states that the announcement can be accessed on the Autolus website and that the full text of the announcement is contained below. The structure, the presence of the RNS header, and the content (announcing the release of data/abstract presentation rather than being the full data set or a comprehensive report) strongly indicate this is a regulatory news service announcement. Since it is a general regulatory announcement that doesn't fit perfectly into specific categories like ER, DIV, or CAP, the most appropriate classification is the general regulatory filing category, RNS. Q1 2021
2021-05-12 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is explicitly labeled with 'RNS Number' and contains a standard header/footer structure associated with regulatory news service announcements from the London Stock Exchange. The content details 'Notification of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs") and Connected Persons,' which involves reporting insider share transactions (purchases and disposals) by executives and related parties. This specific type of filing, reporting director's dealings, maps directly to the 'Director's Dealing (Code: DIRS)' definition. Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2021-05-12 English
Achilles reports Q1 financial results
Earnings Release Classification · 99% confidence The document is an RNS announcement from Syncona Limited, dated May 11, 2021, noting that its portfolio company, Achilles Therapeutics Plc, announced its financial results for the first quarter ended March 31, 2021. The text explicitly states that the announcement 'can be accessed on Achilles' website' and contains the 'full text of the announcement from Achilles... below.' The content below the initial notification is the detailed press release from Achilles, which includes 'Financial Highlights' and full 'Condensed Consolidated Balance Sheets (Unaudited)' and 'Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)' for the three months ended March 31, 2021. Since this is a comprehensive report containing detailed financial statements for a period shorter than a year (Q1 2021), it fits the definition of an Interim/Quarterly Report (IR). Although it is presented via an RNS wrapper, the core content is the full quarterly report, not just a brief announcement of its publication (which would be RPA/RNS). The presence of 'Condensed Consolidated Balance Sheets (Unaudited)' and 'Statements of Operations' for a specific quarter strongly points to IR. Q1 2021
2021-05-11 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.